Novo Nordisk A/S stock is trading -35.2% below its average target price of $84.94 after dropping -20.2% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $60.55292 to $110.04278 per share.
The stock has a very low short interest at 0.7%, and a short ratio of 3.04. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 9.9% of Novo Nordisk A/S's shares being owned by this investor type.
Institutions Invested in Novo Nordisk A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Jennison Associates LLC | 1% | 18,822,002 | $1,036,057,065 |
| 2025-03-31 | Bank of America Corporation | 0% | 14,792,624 | $814,259,960 |
| 2025-03-31 | LOOMIS SAYLES & CO L P | 0% | 12,388,242 | $681,910,758 |
| 2025-03-31 | Morgan Stanley | 0% | 12,319,787 | $678,142,652 |
| 2025-03-31 | Fisher Asset Management, LLC | 0% | 11,871,236 | $653,452,163 |
| 2025-03-31 | Sarofim, Fayez & Co | 0% | 11,212,499 | $617,191,986 |
| 2025-03-31 | Folketrygdfondet | 0% | 9,521,912 | $524,133,628 |
| 2025-03-31 | FMR, LLC | 0% | 9,632,932 | $530,244,724 |
| 2025-03-31 | Capital International Investors | 0% | 9,511,545 | $523,562,977 |
| 2025-03-31 | Renaissance Technologies, LLC | 0% | 6,821,396 | $375,483,730 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Novo Nordisk A/S.
